Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class ant... Read more
Vaxcyte
5 followers
Enable Medicine
5 followers
Discovery Life Sciences
3 followers
Tango Therapeutics
3 followers
Mineralys Therapeutics
3 followers
Forge Biologics
2 followers
Apogee Therapeutics
2 followers
Entos
1 follower
Odyssey Therapeutics
4 followers
Strand Therapeutics
3 followers
I Peace
1 follower
Arc Institute
4 followers